FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

D.C. 20549	OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Brockstedt Dirk G.</u>						2. Issuer Name <b>and</b> Ticker or Trading Symbol ADURO BIOTECH, INC. [ ADRO ]								ck all applica Director	tionship of Reporting Pers : all applicable) Director Officer (give title below) Sr. VP of Research		10% Ow	ner		
(Last) (First) (Middle) C/O ADURO BIOTECH, INC.						3. Date of Earliest Transaction (Month/Day/Year) 12/10/2015								below)			Other (specify below)  ch and Dev.			
(Street)		CA 94710					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	state)	(Zip)																	
			ble I - No							, Dis	posed of			_			1-			
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)		Execution Date,		3. Transaction Code (Instr. 8)				(A) or 3, 4 and 5)	5. Amour Securities Beneficia Owned F	s llly ollowing	6. Owne Form: D (D) or In (I) (Instr	oirect li direct E . 4) C	7. Nature of Indirect Beneficial Ownership					
							Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				nstr. 4)				
Common Stock			12/1	12/10/2015				M		25,000	Α	\$1.45	25,	000	D					
Common Stock			12/1	12/10/2015				S <sup>(1)</sup>		5,735	D	\$29.43(2	19,	265	D					
Common Stock			12/1	12/10/2015				S <sup>(1)</sup>		13,289	D	\$29.98(3	5,9	976	D					
Common Stock			12/1	2/10/2015				S <sup>(1)</sup>		2,600	D	\$29.56(4	3,376		D					
Common Stock			12/1	2/10/2015				S <sup>(1)</sup>		3,376	D	\$30.03(5	) (	)	D					
			Table II								osed of, c			Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	4. Transa Code ( 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exerc Expiration Da (Month/Day/		ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti	e Constant of the constant of	0. Ownership orm: Orect (D) r Indirect ) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	ion(s)				
Stock Option (Right to Buy)	\$1.45	12/10/2015			M			25,000	(6	5)	01/09/2025	Common Stock	25,000	\$0.00	303,062		D			
Stock Option (right to buy)	\$30.16	12/10/2015			A		15,000		(7	"	12/09/2025	Common Stock	15,000	\$0.00	15,000		D			

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were affected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2015.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$28.74 to \$29.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$29.75 to \$30.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$28.82 to \$29.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$29.84 to \$30.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- 6. The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of January 10, 2015.
- 7. The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of December 10, 2015.

## Remarks:

/s/ Jennifer Lew, Attorney-in-

12/14/2015

Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.